AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8657211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 8657211 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 310
Study 1725535 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 0
Study 1725535 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nitroglycerin
Number of subjects: 0
Study 7084585 — intervention group
Group type: EXPERIMENTAL
Intervention: Homogenised meal
Number of subjects: 5
Study 7084585 — intervention group
Group type: COMPARATOR
Intervention: Solid-liquid meal
Number of subjects: 5
Study 31722690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention (Cool Kids), 10 sessions
Number of subjects: 228
Study 31722690 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care from pediatrician
Number of subjects: 228
Study 31722690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention (Cool Kids)
Number of subjects: 228
Study 27845956 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time systolic blood pressure (BP)
Number of subjects: 50
Study 27845956 — intervention group
Group type: COMPARATOR
Intervention: Daytime systolic blood pressure (BP)
Number of subjects: 50
Study 25268286 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 28
Study 25268286 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility Training (FLEX)
Number of subjects: 28
Study 25268286 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Strength and Flexibility (ST + FLEX)
Number of subjects: 28
Study 25268286 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Flexibility and Strength (FLEX + ST)
Number of subjects: 28
Study 25268286 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 28
Study 23106829 — intervention group
Group type: COMPARATOR
Intervention: Sugar (S)
Number of subjects: 92
Study 23106829 — intervention group
Group type: COMPARATOR
Intervention: Regumate (R)
Number of subjects: 92
Study 21352389 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication with citalopram
Number of subjects: 41
Study 21352389 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication with reboxetine
Number of subjects: 41
Study 21352389 — intervention group
Group type: COMPARATOR
Intervention: Exclusive treatment with psychotherapy
Number of subjects: 41
Study 18045825 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO class IV
Number of subjects: 83
Study 18045825 — intervention group
Group type: COMPARATOR
Intervention: IV‐Q
Number of subjects: 83
Study 18045825 — intervention group
Group type: COMPARATOR
Intervention: WHO class III (>/=50%) and WHO‐IV
Number of subjects: 83
Study 18045825 — intervention group
Group type: COMPARATOR
Intervention: ISN/RPS class IV‐S and IV‐G
Number of subjects: 83
Study 16925808 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81-100 mg/day)
Number of subjects: 0
Study 16925808 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (100-200 mg/day)
Number of subjects: 0
Study 14726734 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention during rehabilitation
Number of subjects: 11
Study 14726734 — intervention group
Group type: COMPARATOR
Intervention: Control group (without music intervention)
Number of subjects: 11
Study 10837300 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (7000 microg retinol equivalents as retinyl palmitate)
Number of subjects: 43559
Study 10837300 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (42 mg all-trans-beta-carotene)
Number of subjects: 43559
Study 10837300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43559
Study 9377905 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic intracranial haemorrhage of unknown aetiology
Number of subjects: 10
Study 8385015 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/amikacin/teicoplanin (group 1)
Number of subjects: 114
Study 8385015 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin/amikacin/tazobactam (group 2)
Number of subjects: 114
Study 8385015 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 114
Study 2871184 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy (16 sessions of progressive relaxation, desensitization, and EMG biofeedback)
Number of subjects: 20
Study 2871184 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 20
Study 2871184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2871184 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (Relaxation and Placebo)
Number of subjects: 20
Study 30417277 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg
Number of subjects: 0
Study 30417277 — intervention group
Group type: COMPARATOR
Intervention: adalimumab 40 mg
Number of subjects: 0
Study 30417277 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 29724486 — intervention group
Group type: EXPERIMENTAL
Intervention: ePROs accessible to physicians
Number of subjects: 40
Study 29724486 — intervention group
Group type: COMPARATOR
Intervention: ePROs inaccessible to physicians (Control)
Number of subjects: 40
Study 28362949 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of influenza vaccine
Number of subjects: 499
Study 28362949 — intervention group
Group type: COMPARATOR
Intervention: 1 dose of influenza vaccine
Number of subjects: 499
Study 29340179 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie Protocol (MP)
Number of subjects: 67
Study 29340179 — intervention group
Group type: EXPERIMENTAL
Intervention: MP and Static Endurance Exercise Group (MPSEEG)
Number of subjects: 67
Study 29340179 — intervention group
Group type: EXPERIMENTAL
Intervention: MP and Dynamic Endurance Exercise Group (MPDEEG)
Number of subjects: 67
Study 29340179 — intervention group
Group type: EXPERIMENTAL
Intervention: MP combined with Dynamic Endurance Exercise
Number of subjects: 67
Study 24073898 — intervention group
Group type: EXPERIMENTAL
Intervention: e-consultation system
Number of subjects: 0
Study 21575100 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 1 mcg·kg(‐1) (F1 group)
Number of subjects: 60
Study 21575100 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2 mcg·kg(‐1) (F2 group)
Number of subjects: 60
Study 21575100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg·kg(‐1) (K group)
Number of subjects: 60
Study 21575100 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 mcg·kg(‐1) plus Ketamine 0.5 mg·kg(‐1) (FK group)
Number of subjects: 60
Study 18465334 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical CMF (oral cyclophosphamide days 1-14, intravenous methotrexate and fluorouracil on days 1 and 8, repeated every 28 days)
Number of subjects: 2213
Study 18465334 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-weekly intravenous CMF
Number of subjects: 2213
Study 18465334 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-weekly intravenous CMF
Number of subjects: 2213
Study 18465334 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical CMF
Number of subjects: 2213
Study 17290563 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (80 mg elementary iron)
Number of subjects: 168
Study 17290563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 17290563 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 168
Study 12847992 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg Vitamin C
Number of subjects: 68
Study 12847992 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g Omega-3 fatty acids
Number of subjects: 68
Study 12847992 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg Vitamin C + 1 g Omega-3 fatty acids
Number of subjects: 68
Study 12847992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 68
Study 11429120 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN‐gamma 0.05 mg/m(2) subcutaneously three times weekly for 48 weeks
Number of subjects: 84
Study 11429120 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 84
Study 11429120 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN‐gamma
Number of subjects: 84
Study 11429120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 9725114 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderation training with ecological momentary assessment (EMA) using an electronic diary (ED) for 8 weeks
Number of subjects: 0
Study 9725114 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 0
Study 7978409 — intervention group
Group type: COMPARATOR
Intervention: Epidural fentanyl (EF), 10 micrograms/mL in saline
Number of subjects: 120
Study 7978409 — intervention group
Group type: EXPERIMENTAL
Intervention: EF with 0.1% bupivacaine
Number of subjects: 120
Study 7978409 — intervention group
Group type: EXPERIMENTAL
Intervention: EF with 0.15% bupivacaine
Number of subjects: 120
Study 7978409 — intervention group
Group type: EXPERIMENTAL
Intervention: EF with 0.2% bupivacaine
Number of subjects: 120
Study 7978409 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 2929911 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.5 mg
Number of subjects: 0
Study 2929911 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 2 mg
Number of subjects: 0
Study 2929911 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 1 mg
Number of subjects: 0
Study 28082332 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9
Study 28082332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 26299230 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 4038
Study 26299230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4038
Study 23810208 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-frontal anodal stimulation (max. current density: 0.331 mA/cm²) during early NREM sleep
Number of subjects: 26
Study 23810208 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 26
Study 23810208 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum tDCS
Number of subjects: 26
Study 21213091 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care + ¡Viva Bien!
Number of subjects: 280
Study 21213091 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 280
Study 19925723 — intervention group
Group type: EXPERIMENTAL
Intervention: Loose larval therapy
Number of subjects: 267
Study 19925723 — intervention group
Group type: EXPERIMENTAL
Intervention: Bagged larval therapy
Number of subjects: 267
Study 19925723 — intervention group
Group type: COMPARATOR
Intervention: Larval therapy (loose and bagged pooled)
Number of subjects: 267
Study 19925723 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel
Number of subjects: 267
Study 19925723 — intervention group
Group type: EXPERIMENTAL
Intervention: Larval therapy
Number of subjects: 267
Study 17174502 — intervention group
Group type: COMPARATOR
Intervention: Barium sulphate alone
Number of subjects: 149
Study 17174502 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium sulphate + iodinated hyperosmolar contrast agent (Gastrografin)
Number of subjects: 149
Study 17174502 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium sulphate + effervescent granules (Carbex)
Number of subjects: 149
Study 17174502 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium sulphate + both iodinated hyperosmolar contrast agent and effervescent granules
Number of subjects: 149
Study 15238971 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive anaesthesia
Number of subjects: 53
Study 15238971 — intervention group
Group type: COMPARATOR
Intervention: Normotensive anaesthesia
Number of subjects: 53
Study 11860218 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 800 microg/daily b.i.d. (n = 66)
Number of subjects: 127
Study 11860218 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 1000 microg/daily b.i.d. (n = 61)
Number of subjects: 127
Study 9550512 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor stimulation for 6 weeks
Number of subjects: 100
Study 9550512 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 100
Study 7835121 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiload Cu250 (MLCu250)
Number of subjects: 200
Study 7835121 — intervention group
Group type: COMPARATOR
Intervention: VCu200
Number of subjects: 200
Study 30261146 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine (9vHPV)
Number of subjects: 21
Study 30261146 — intervention group
Group type: COMPARATOR
Intervention: quadrivalent HPV vaccine (qHPV)
Number of subjects: 21
Study 30261146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines (9vHPV and qHPV)
Number of subjects: 21
Study 28923786 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNERGY
Number of subjects: 291
Study 28923786 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNERGY half-dose
Number of subjects: 291
Study 28923786 — intervention group
Group type: COMPARATOR
Intervention: PE (PROMUS Element EES)
Number of subjects: 291
Study 28923786 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 291
Study 27159854 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal injection of 2 mL of 1% lidocaine + epinephrine 1:100,000 + GPC injection
Number of subjects: 50
Study 27159854 — intervention group
Group type: COMPARATOR
Intervention: Transnasal injection of 2 mL of 1% lidocaine + epinephrine 1:100,000 (monotherapy)
Number of subjects: 50
Study 23928675 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nepafenac
Number of subjects: 120
Study 23928675 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Systane Ultra)
Number of subjects: 120
Study 23390832 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once daily
Number of subjects: 77
Study 23390832 — intervention group
Group type: COMPARATOR
Intervention: Darifenacin 7.5 mg once daily
Number of subjects: 77
Study 20733445 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system
Number of subjects: 165
Study 20733445 — intervention group
Group type: COMPARATOR
Intervention: Oral medroxyprogesterone acetate
Number of subjects: 165
Study 18215612 — intervention group
Group type: EXPERIMENTAL
Intervention: ximelagatran with aspirin
Number of subjects: 1883
Study 18215612 — intervention group
Group type: COMPARATOR
Intervention: aspirin alone (placebo)
Number of subjects: 1883
Study 16402749 — intervention group
Group type: EXPERIMENTAL
Intervention: Outward-turning wings
Number of subjects: 0
Study 16402749 — intervention group
Group type: EXPERIMENTAL
Intervention: Inward-turning wings
Number of subjects: 0
Study 16402749 — intervention group
Group type: EXPERIMENTAL
Intervention: Figural changes that shift the center of gravity
Number of subjects: 0
Study 12858227 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% MNDA
Number of subjects: 0
Study 12858227 — intervention group
Group type: COMPARATOR
Intervention: 1% Deet
Number of subjects: 0
Study 10227004 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms/day 17 beta‐estradiol for 14 weeks, combined with oral medroxyprogesterone acetate 10 mg/day during the last 2 weeks
Number of subjects: 40
Study 10227004 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 weeks, combined with oral medroxyprogesterone acetate 10 mg/day during the last 2 weeks
Number of subjects: 40
Study 8929263 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous radio-frequency neurotomy (multiple lesions made, electrode temperature raised to 80 degrees C)
Number of subjects: 24
Study 8929263 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (identical procedure but radio-frequency current not turned on)
Number of subjects: 24
Study 8929263 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous radio-frequency neurotomy
Number of subjects: 24
Study 8929263 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 24
Study 1831505 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline (TC) fiber therapy
Number of subjects: 107
Study 1831505 — intervention group
Group type: COMPARATOR
Intervention: Scaling
Number of subjects: 107
Study 1831505 — intervention group
Group type: COMPARATOR
Intervention: Control fiber (fibers without drug)
Number of subjects: 107
Study 1831505 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 107
Study 6181041 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with intradermal administration of methanol extraction residue of BCG (MER) and split course megavoltage radiotherapy (5,000 rad over 7 weeks)
Number of subjects: 44
Study 6181041 — intervention group
Group type: COMPARATOR
Intervention: Split course megavoltage radiotherapy alone (5,000 rad over 7 weeks)
Number of subjects: 44
Study 30089135 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 4 mg
Number of subjects: 121
Study 30089135 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 8 mg
Number of subjects: 121
Study 30089135 — intervention group
Group type: COMPARATOR
Intervention: Active placebo procedure
Number of subjects: 121
Study 30089135 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (both doses)
Number of subjects: 121
Study 30089135 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucid dreams compared to non-lucid dreams
Number of subjects: 121
Study 27289121 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 5380
Study 27289121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5380
Study 27289121 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin after MI
Number of subjects: 5380
Study 27289121 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin after HHF
Number of subjects: 5380
Study 27289121 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin after stroke
Number of subjects: 5380
Study 27289121 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin after UA
Number of subjects: 5380
Study 24903323 — intervention group
Group type: EXPERIMENTAL
Intervention: Football Group (FG)
Number of subjects: 26
Study 24903323 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training Group (ST)
Number of subjects: 26
Study 24903323 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CO)
Number of subjects: 26
Study 23461218 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese Matrix Program (J-MAT)
Number of subjects: 60
Study 23461218 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 20170591 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural grape juice (18 ml/kg/day) for 1 month
Number of subjects: 30
Study 20170591 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural pomegranate juice (240 ml/day) for 1 month
Number of subjects: 30
Study 19102149 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial patellofemoral ligament overlap and lateral patellar retinaculum release
Number of subjects: 100
Study 19102149 — intervention group
Group type: COMPARATOR
Intervention: Lateral patellar retinaculum release (control)
Number of subjects: 100
Study 16113403 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling by health and nutrition workers at multiple contacts on exclusive breastfeeding for 6 months and appropriate complementary feeding practices thereafter
Number of subjects: 0
Study 16113403 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 11961400 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol 0 microg (placebo)
Number of subjects: 162
Study 11961400 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 1 microg
Number of subjects: 162
Study 11961400 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 1.5 microg
Number of subjects: 162
Study 11961400 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 2 microg
Number of subjects: 162
Study 10406247 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pharyngeal anesthesia with 2% tetracaine/14% benzocaine spray
Number of subjects: 95
Study 10406247 — intervention group
Group type: COMPARATOR
Intervention: Conscious sedation alone (no pharyngeal anesthesia)
Number of subjects: 95
Study 7486274 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane-N2O-O2 (IF)
Number of subjects: 40
Study 7486274 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-N2O-O2 (PF)
Number of subjects: 40
Study 2209278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (2 gm) with metronidazole (1.5 gm)
Number of subjects: 173
Study 2209278 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin (3 mg/kg/day for five days) with metronidazole (1.5 gm)
Number of subjects: 173
Study 6993501 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Therapy (BT)
Number of subjects: 60
Study 6993501 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-relaxation (SR)
Number of subjects: 60
Study 6993501 — intervention group
Group type: COMPARATOR
Intervention: Transcendental Meditation (TM)
Number of subjects: 60
Study 6993501 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (WL)
Number of subjects: 60
Study 31259738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir (1% gel)
Number of subjects: 0
Study 31259738 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine (25 mg in vaginal ring)
Number of subjects: 0
Study 28937531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal DEX (2 μg/kg)
Number of subjects: 39
Study 27307536 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 397
Study 27307536 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 397
Study 27307536 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 397
Study 27307536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study 24908205 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant
Number of subjects: 255